URGN
HealthcareUroGen Pharma Ltd. · Biotechnology · $1B
What is UroGen Pharma Ltd.?
UroGen Pharma is a biotechnology company focused on developing and commercializing treatments for specialty cancers and urothelial diseases. Headquartered in Princeton, New Jersey, the company targets conditions that have historically lacked effective non-surgical options.
UroGen generates revenue primarily through its proprietary RTGel technology — a reverse thermal gelation hydrogel that enhances how existing drugs are delivered to the urinary tract. Its commercialized product, Jelmyto, treats low-grade upper tract urothelial carcinoma. The company is advancing UGN-102 through Phase III trials for non-muscle invasive bladder cancer and developing UGN-301 for high-grade bladder cancer. Collaborations with MD Anderson and licensing agreements with Allergan and Agenus further support its pipeline.
UroGen Pharma was incorporated in 2004 and is headquartered in Princeton, New Jersey.
- RTGel — proprietary hydrogel drug-delivery platform
- Jelmyto — approved treatment for upper tract urothelial carcinoma
- UGN-102 — Phase III candidate for non-muscle invasive bladder cancer
- UGN-301 — investigational therapy for high-grade bladder cancer
- Strategic research collaboration with MD Anderson Cancer Center
Is URGN a Good Stock to Buy?
UQS Score rates URGN as Good overall, reflecting a mixed but developing profile across the five quality pillars.
The Risk pillar stands out as a relative strength, suggesting the company's financial structure carries manageable downside exposure for its stage. The Growth pillar also rates Good, consistent with a company advancing a commercial product while pushing multiple candidates through late-stage trials. Valuation is rated Good, indicating the market price does not appear stretched relative to the company's current fundamentals.
The Quality and Moat pillars both rate Weak, which is common for early-commercial biotechs — durable competitive advantages and consistent profitability are still being established.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does URGN pay dividends?
No — UroGen Pharma Ltd. does not currently pay a dividend.
URGN does not pay a dividend. As an early-commercial biotechnology company, UroGen reinvests available capital into clinical development, regulatory activities, and commercialization efforts. Investors in this stage of biotech typically seek returns through pipeline progress and potential revenue growth rather than income distributions.
When does URGN report earnings?
UroGen Pharma reports earnings on a quarterly cadence, typical for US-listed equities.
Each quarterly report provides an update on Jelmyto commercial performance, pipeline milestones, and cash runway — all closely watched by investors tracking the company's path toward sustained profitability. Clinical trial readouts can significantly influence how the market interprets any given quarter's results.
For the most recent quarter's results and guidance, visit UroGen Pharma's investor relations page directly.
URGN Price History
+42.1% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in UroGen Pharma Ltd.?
Based on UroGen Pharma Ltd.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
URGN Long-term Outlook
UroGen's fundamental outlook is shaped by the interplay between its Good Growth profile and its Weak Quality and Moat ratings. Near-term trajectory depends heavily on continued Jelmyto adoption and Phase III data from UGN-102. A successful readout could meaningfully expand the addressable market and shift the Quality profile over time. The Strong Risk rating suggests the company is not in immediate financial distress, providing a degree of runway to execute on its pipeline.
Growth drivers
- Expanding commercial uptake of Jelmyto in urothelial carcinoma
- Phase III data readouts for UGN-102 in bladder cancer
- Potential label expansions and new indications via pipeline candidates
Key risks
- Clinical trial failure or delays for UGN-102 or UGN-301
- Weak Moat rating reflects limited pricing power and competitive exposure
- Early-commercial stage means profitability remains uncertain
URGN vs Peers
UroGen operates in a competitive specialty oncology and urology space alongside several focused biotechs.
Xeris focuses on ready-to-use formulations for endocrine and metabolic conditions, giving it a different therapeutic focus than UroGen's urothelial-cancer specialization.
ORIC targets mechanisms of cancer treatment resistance, competing in the broader oncology pipeline space but without UroGen's commercialized urothelial product.
Aktis is developing targeted radiotherapeutics for cancer, representing a distinct modality compared to UroGen's hydrogel-based intravesical delivery approach.
Frequently Asked Questions
What does UroGen Pharma do?
UroGen Pharma develops and commercializes treatments for specialty cancers and urothelial diseases. Its core technology, RTGel, is a hydrogel platform that improves how drugs are delivered directly to the urinary tract. The company's approved product, Jelmyto, treats upper tract urothelial carcinoma, while its pipeline targets additional forms of bladder cancer.
Does URGN pay dividends?
URGN does not currently pay a dividend. The company is in an early-commercial stage and prioritizes reinvesting capital into clinical development and commercialization. Investors in URGN are generally seeking growth from pipeline advancement rather than income.
When does URGN report earnings?
UroGen Pharma reports on a quarterly cadence, consistent with US-listed public companies. Each report typically includes Jelmyto revenue updates and pipeline progress. For exact dates, check UroGen's investor relations page.
Is URGN a good stock to buy?
UQS Score rates URGN as Good overall. The Risk and Growth pillars are relative strengths, while Quality and Moat are rated Weak — reflecting the realities of an early-commercial biotech. Whether URGN fits your portfolio depends on your risk tolerance and investment horizon. View the full pillar breakdown on UQS Pro.
Is URGN overvalued?
The UQS Valuation pillar for URGN is rated Good, suggesting the current market price does not appear stretched relative to the company's fundamentals. For the complete valuation metrics behind this rating, a UQS Pro account provides the full breakdown.
How does URGN compare to its competitors?
UroGen differentiates itself through its proprietary RTGel delivery platform and a commercialized product in Jelmyto — advantages that pipeline-stage peers like ORIC and Aktis Oncology have not yet achieved. Xeris Biopharma operates in a different therapeutic area entirely. The UQS platform allows side-by-side pillar comparisons across these names.
What is URGN's market cap bracket?
URGN is classified as a small-cap stock. This places it in a segment of the market that can offer meaningful growth potential but also carries higher volatility and liquidity risk compared to large- or mega-cap peers.
Who founded UroGen Pharma?
UroGen Pharma was incorporated in 2004. Founding and leadership history is publicly available through the company's official filings and investor relations materials for those seeking detailed background.
Is URGN a long-term quality investment?
From a long-term quality perspective, URGN's Weak Moat and Quality ratings indicate the company has not yet built the durable competitive advantages or consistent financial performance associated with high-conviction long-term holdings. However, the Good Growth and Strong Risk ratings suggest meaningful upside potential if pipeline milestones are achieved. UQS Pro members can track how these pillar ratings evolve over time.
What is the main competitive advantage of UroGen Pharma?
UroGen's primary differentiator is its RTGel hydrogel platform, which allows drugs to be retained longer in the urinary tract — potentially improving efficacy compared to standard liquid formulations. This proprietary delivery technology underpins both its approved product and its pipeline candidates.
What sector does URGN belong to?
URGN operates in the Healthcare sector, specifically within biotechnology. The company focuses on a niche within oncology — urothelial and bladder cancers — where it competes with both large pharmaceutical companies and smaller specialty biotechs.
Is URGN a growth stock or value stock?
Based on its UQS profile, URGN leans toward the growth category. The Growth pillar is rated Good and Valuation is also rated Good, meaning the market has not yet priced in an extreme premium. It is not a traditional value stock given its early-commercial stage and lack of consistent profitability.
Unlock Full URGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View exact scores across all five UQS pillars
- ✓Access complete financial metrics and trend data
- ✓Compare URGN side-by-side with sector peers
- ✓Track pillar changes as new data is released
- ✓Screen for stocks with similar quality profiles
Pro Analysis
URGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 52.6 | 33.3 | 25.0 | 73.9 | 82.4 | 72.6 | +0.2 |
| May 21, 2026 | 52.4 | 33.3 | 25.0 | 73.9 | 82.4 | 71.4 | -0.2 |
| May 15, 2026 | 52.6 | 33.3 | 25.0 | 73.9 | 82.4 | 72.7 | +0.4 |
| May 14, 2026 | 52.2 | 33.3 | 25.0 | 73.9 | 82.4 | 69.9 | 0.0 |
| May 12, 2026 | 52.2 | 33.3 | 25.0 | 73.9 | 82.4 | 69.6 | 0.0 |
| May 7, 2026 | 52.2 | 33.3 | 25.0 | 73.9 | 82.4 | 69.8 | -0.5 |
| May 3, 2026 | 52.7 | 33.3 | 25.0 | 73.9 | 82.4 | 73.2 | +0.2 |
| Apr 26, 2026 | 52.5 | 33.3 | 25.0 | 73.9 | 82.4 | 72.0 | +0.2 |
| Apr 19, 2026 | 52.3 | 33.3 | 25.0 | 73.9 | 82.4 | 70.5 | -0.4 |
| Apr 15, 2026 | 52.7 | 33.3 | 25.0 | 73.9 | 82.4 | 73.5 | +0.4 |
URGN — Pillar Breakdown
Quality
— 33.3/100 (25%)UroGen Pharma Ltd. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 73.9/100 (20%)UroGen Pharma Ltd. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 82.4/100 (15%)UroGen Pharma Ltd. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 72.6/100 (15%)UroGen Pharma Ltd. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 25/100 (25%)UroGen Pharma Ltd. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for URGN.
Score Composition
Financial Data
More Stock Analysis
How is the URGN UQS Score Calculated?
The UQS (Unified Quality Score) for UroGen Pharma Ltd. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses UroGen Pharma Ltd.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether UroGen Pharma Ltd. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.